Inflammatory markers and platelet aggregation tests as predictors of hemoglobin and endogenous erythropoietin levels in hemodialysis patients

Nephron

Volumn 91, Issue 4, 2002, Pages 671-681

  Borawski, Jacek ^a   Pawlak, Krystyna ^a   Myśliwiec, Michał ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Anemia; Endothelium; Erythropoietin; Immunoglobulin M; Inflammation; Lipoprotein(a); Platelet aggregation; Ristocetin; Von Willebrand factor

Indexed keywords

ADENOSINE DIPHOSPHATE; ALBUMIN; ALPHA 1 ANTITRYPSIN; ALUMINUM; BIOLOGICAL MARKER; BUFFER; C REACTIVE PROTEIN; CHOLESTEROL; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; FIBRINOGEN; HEMOGLOBIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 6; LIPOPROTEIN A; LIVER ENZYME; OROSOMUCOID; PARATHYROID HORMONE; PHOSPHORUS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RISTOCETIN; THROMBOMODULIN; THYROTROPIN; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

ADULT; AGE; AGED; ANEMIA; ARTICLE; BLOOD; BLOOD ANALYSIS; BODY MASS; CATABOLISM; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; ENDOTHELIUM LESION; FEMALE; GENDER; HEMODIALYSIS; HUMAN; IMPEDANCE; INFLAMMATION; IRON METABOLISM; KIDNEY FAILURE; KIDNEY FUNCTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OPTICAL AGGREGOMETRY; PARATHYROID GLAND; PLASMA; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN METABOLISM; THROMBOCYTE AGGREGATION; THYROID GLAND; VIRUS HEPATITIS; ADOLESCENT; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

ADOLESCENT; ADULT; AGED; ANEMIA; BIOLOGICAL MARKERS; COMPARATIVE STUDY; CROSS-SECTIONAL STUDIES; ERYTHROPOIETIN; FEMALE; HEMOGLOBINS; HUMAN; INFLAMMATION; MALE; MIDDLE AGE; PLATELET AGGREGATION; RENAL DIALYSIS; SUPPORT, NON-U.S. GOV'T; HUMANS; MIDDLE AGED;

EID: 0035995366     PISSN: 00282766     EISSN: None     Source Type: Journal    
DOI: 10.1159/000065030     Document Type: Article

References (37)

1. NKF - DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure
2. Inflammation, serum C-reactive protein, and erythropoietin resistance
3. Acute-phase proteins and other systemic responses to inflammation
4. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients
5. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients
6. Anemia in hemodialysis patients: Variables affecting this outcome predictor
7. Early prediction of response to recombinant human erythropoietin in patients with anemia of renal failure by serum transferrin receptor and fibrinogen
8. High lipoprotein(a) levels in chronic hemodialysis patients are closely related to the acute phase reaction
9. Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure
10. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients
11. Increased cardiovascular risk factors and features of endothelial activation and dysfunction in dialyzed uremic patients
12. Endothelial dysfunction marker von Wille-brand factor antigen in haemodialysis patients: Associations with pre-dialysis blood pressure and the acute phase response
13. Circulating levels of plasminogen activator inhibitor type-1, tissue plasminogen activator, and thrombomodulin in hemodialysis patients: Biochemical correlations and role as independent predictors of coronary artery stenosis
14. Inverse relationships between haemoglobin and ristocetin-induced platelet aggregation in haemodialysis patients under erythropoietin therapy
15. Variables affecting hemoglobin level in hemodialysis patients
16. Methods for studying the von Willebrand factor-platelet interactions
17. Vascular biology of von Wille-brand factor
18. Comparison of different assays for von Willebrand factor in hemodialysis patients
19. Cytokines, platelet production and hemostasis
20. A study of parenteral iron regimens in hemodialysis patients
21. 1 on human platelet aggregation in whole blood in vitro
22. Aggregation of blood platelets by adenosine diphosphate and its reversal
23. Aluminium toxicity in dialysis patients: No evidence for a threshold serum aluminium concentration
24. Improved immunoglobulin production in dialysis patients treated with recombinant erythropoietin
25. Complications of bioincompatibility of hemodialysis membranes
26. Endothelial cells in physiology and in the pathophysiology of vascular disorders
27. Soluble thrombomodulin is associated with viral hepatitis, blood pressure, and medications in haemodialysis patients
28. Atherogenic lipoproteins, oxidative stress, and cell deaths
29. A potential basis for thrombotic risks associated with lipoprotein(a)
30. Influence of hematocrit on the measurement of lipoproteins demonstrated by the example of lipoprotein(a)
31. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia and mortality in hemodialysis patients
32. Cardiovascular disease, fibrinogen and the acute phase response associations with lipids and blood pressure in patients with chronic renal disease
33. Plasminogen activator inhibitor-1 activity in chronic renal disease and dialysis
34. Role of cytokines in the response to erythropoietin in hemodialysis patients
35. Dialysate related cytokine induction and response to recombinant erythropoietin in haemodialysis patients
36. Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: Role of INF-gamma and TNF-alpha
37. Diagnostic and prognostic significance of the acute-phase proteins